Miyamoto Yuji, Suyama Koichi, Baba Hideo
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan.
Cancer Center, Kumamoto University Hospital, Kumamoto 860-8556, Japan.
Int J Mol Sci. 2017 Apr 2;18(4):752. doi: 10.3390/ijms18040752.
Outcomes for metastatic colorectal cancer (mCRC) patients have been improved by treatment with anti-epidermal growth factor receptor (anti-EGFR) antibodies, particularly when combined with predictive biomarkers to select patients lacking mutations. New technologies such as liquid biopsy and next-generation sequencing have revealed that potential mechanisms of resistance to anti-EGFR therapies act through acquired mutations of and the ectodomain. Mutations in cross-talking molecular effectors that participate in downstream EGFR signaling are also negative predictors for anti-EGFR therapy. In the current review, we describe recent advances in anti-EGFR therapy and discuss new treatment strategies to target downstream RAS-MAPK signaling in mCRC.
抗表皮生长因子受体（anti-EGFR）抗体治疗改善了转移性结直肠癌（mCRC）患者的预后，尤其是与预测性生物标志物联合使用以选择缺乏突变的患者时。液体活检和下一代测序等新技术表明，抗EGFR治疗耐药的潜在机制是通过 和 胞外结构域的获得性突变起作用。参与下游EGFR信号传导的相互作用分子效应器中的突变也是抗EGFR治疗的阴性预测指标。在本综述中，我们描述了抗EGFR治疗的最新进展，并讨论了针对mCRC中下游RAS-MAPK信号传导的新治疗策略。
